Claims
- 1. A post-treatment process for making an inkjet printable, polymeric composition or a strongly-swellable polymeric hydrogel which comprises providing a stable, aqueous two-phase polymeric composition by the steps of forming a reaction mixture in a reaction vessel of a water-soluble vinyl monomer, optionally with one or more water-soluble comonomers, a predetermined amount of a first crosslinking agent, and water, heating the mixture, then periodically adding a predetermined amount of a free radical initiator, and polymerizing at a suitable temperature, optionally removing said resultant two-phase polymeric composition from the reaction vessel, optionally including an added active material, adding a predetermined amount of post-treatment crosslinker, optionally blending a proteinaceous and/or water compatible material thereto, optionally coating the mixture onto a support, and optionally heating the mixture.
- 2. The product of the process of claim 1 which is an inkjet printable polymeric composition capable of forming a water-resistant polymeric coating on a substrate.
- 3. The product of the process of claim 1 which is a hydrogel composition.
- 4. A process according to claim 1 which is post-treated at a temperature from room temperature to about 200° C.
- 5. A process according to claim 1 in which at least 0.02% by weight of post-treatment crosslinker is added to the two-phase composition.
- 6. A process according to claim 1 which includes a proteinaceous material.
- 7. A process according to claim 1 in which said polymerization crosslinker is present in an amount of 0.02-0.5 wt. % based on monomers.
- 8. The product of the process of claim 1 which is a strongly-swellable hydogel having a Brookfield viscosity of at least 100,000 cps.
- 9. A process according to claim 1 where the active is present and is a cosmetic, nutritional or pharmaceutical active material.
- 10. The product of the process of claim 8.
- 11. The product of the process of claim 9.
- 12. A process according to claim 1 wherein the post-treatment crosslinker is an aziridine, a glycerol glycidyl ether, tris(2,3-epoxypropyl) isocyanurate, trimethylolpropane triglycidyl ether, diglycidyl ether of 1,4 butanediol, diglycidyl 1,2-cyclo-hexanecarboxylate, neopentyl glycol diglycidyl ether, and 3-glycidoxypropyltrimethoxysilane, β-(3,4-epoxycyclohexyl) ethyltriethoxysilane, glycerol propoxylate triglycidyl ether or glycidol and boric acid.
- 13. A product of the process of claim 1 which is further treated with glycidol.
- 14. A product of the process of claim 1 which is further treated with 1-aziridineethanol.
CROSS-REFERENCE TO RELATED U.S. PATENT APPLICATIONS
[0001] This application is a continuation-in-part of co-pending U.S. patent application Ser. Nos. 09/663,010, filed Sep. 15, 2000, 09/784,268, filed Feb. 15, 2001, and 09/881,906, filed Jun. 15, 2001.
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09663010 |
Sep 2000 |
US |
Child |
10388697 |
Mar 2003 |
US |
Parent |
09784268 |
Feb 2001 |
US |
Child |
10388697 |
Mar 2003 |
US |
Parent |
09881906 |
Jun 2001 |
US |
Child |
10388697 |
Mar 2003 |
US |